Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.

In this report, we describe a patient who developed asymptomatic nodules on her legs, with complete, spontaneous resolution, while on vemurafenib therapy. A causal relationship was considered likely because of the timing of occurrence and the absence of other potential causes after extensive assessment. Vemurafenib therapy was continued at full dosage and no recurrences were observed. We believe that management of lobular panniculitis associated with selective BRAF inhibitors should vary according to the clinical presentation, degree of systemic involvement, and presence of joint inflammation. Physicians should be aware of this emergent side effect. Treatment discontinuation should be considered on a case-by-case basis because the condition may resolve spontaneously. PMID: 24021375 [PubMed - in process]
Source: Dermatol Online J - Category: Dermatology Authors: Tags: Dermatol Online J Source Type: research